%D9%88%D8%B1%D9%85_%D8%A8%D8%B7%D8%A7%D9%86%D9%8A_%D8%B9%D8%B5%D8%A8%D9%8ACategory:EpendymomaEpendymomEpendymomEpendymomaEpendimoma%C3%89pendymomeEpendimoma%E4%B8%8A%E8%A1%A3%E8%85%ABEpendymoomWy%C5%9Bci%C3%B3%C5%82czakEpendimoma%D0%AD%D0%BF%D0%B5%D0%BD%D0%B4%D0%B8%D0%BC%D0%BE%D0%BC%D0%B0%D0%95%D0%BF%D0%B5%D0%BD%D0%B4%D0%B8%D0%BC%D0%BE%D0%BCQ1346753
about
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS TumorsA Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid TumorA Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain TumorsBevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerIspinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaMaintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed EpendymomaRitonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade GliomaVorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsSunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma3T MRI Biomarkers of Glioma Treatment ResponseEGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS TumorsPositron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsEtoposide Plus Cisplatin in Treating Patients With Recurrent EpendymomasPhase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent EpendymomaEfficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent GliomasExploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System TumorsAflac ST0901 CHOANOME - Sirolimus in Solid TumorsCarboplatin and Bevacizumab for Recurrent EpendymomaYoga Therapy in Treating Patients With Malignant Brain TumorsBafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain MetastasesInfusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa EpendymomaHER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS TumorsPhase I Study of APX005M in Pediatric CNS TumorsA Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research PurposesVemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord EpendymomaPembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaA Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With GliomasUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain TumorsSocial Determinants of Health in Glioblastoma PopulationStudy of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 TrialRare CNS Tumors Outcomes &RiskOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
P1050
Stem cells of ependymomaSupratentorial extraventricular anaplastic ependymoma in an adult with repeated intratumoral hemorrhageMicrosurgical resection of tumors of the lateral and third ventricles: operative corridors for difficult-to-reach lesionsMolecular genetics of ependymomaEvaluation of the diagnostic performance of magnetic resonance spectroscopy in brain tumors: a systematic review and meta-analysis.Imaging of ependymomas: MRI and CT.Spinal cord ependymomas and the appearance of other de novo tumors: a systematic review.The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Cerebellar ependymoma with overlapping features of clear-cell and tanycytic variants mimicking hemangioblastoma: a case report and literature review.[Mount Fuji sign in postoperative period after surgery for ependymoma of the third ventricle (V3): case report and review of the literature].
P921
Q61865052-5C9F2C63-EC0C-4943-931B-A5B905E47050Q61909903-9D47D311-CF00-406D-9976-16E4516987E9Q61915079-B37E4551-8EED-4D4F-B990-D65B3507A97EQ61915531-9688FF31-A783-48F6-92B5-31CA44FBAC85Q61917913-6C7ECBC9-74D6-4DB7-93DE-A648C36D75A5Q61934710-5D3C0C09-C7D2-4C93-8B8A-79D1C48AD223Q61936459-5873F8E3-0924-4848-BCA9-E12B8D001D35Q61936704-4D03FC8E-E0FF-447C-B729-238C79D99BDEQ61938124-0FC399E1-B4D6-4EA7-807C-CFE6D12A9A7CQ61957039-F32D25DF-CD06-4211-96FF-23F2EF87D404Q61969599-FD486D63-1786-4A8F-B73C-788EECACC2B0Q62063143-676D6492-D3F9-4504-8C98-957567494CE4Q62105305-4A3104D8-61FA-472F-8E06-AB9B90BA29F7Q62111032-A0E001A8-803F-4DED-90DF-A0D250C31084Q63318331-29553180-55A1-465A-A95F-269EAAD8E19FQ63320245-8AB772F0-C64A-488D-9573-A7A18B2E13C1Q63321689-6F87347F-18DF-4404-A8B2-D2C41136318DQ63337746-82D75058-FF16-47CB-AA42-0155AB0E5B25Q63339152-D4961AB8-AC9E-405C-B4EF-7176BCFF27C5Q63340802-656C4F4A-6635-4B74-9B33-6DD9474D9C45Q63340808-2CA17562-95A8-4EAF-A1F1-E0587AF3FA75Q63397180-A7600C54-1D68-4261-A5FC-CEA6D1330FE8Q63399090-CB16BEAC-8E7E-4A23-A264-CA228960D995Q63405357-8AF2FAC3-5B01-41EC-AD7D-3E747A93E0FBQ63572844-F37FF909-C473-4996-A915-1357DAC9AB35Q63573040-72A515FF-6D4F-4B9B-B338-8FA387CF8AB6Q63573228-0D6FE035-C4A7-4EF5-8021-26B92C4C3D34Q63573333-438C7492-9360-41D5-AB27-A36103C0D152Q63576593-A52BBB45-FD3B-4F1D-8EF0-819BA822D8DAQ63576602-FFF340AF-7CF6-43BE-8A70-8673C6CDD21FQ63587860-45CD01FA-E750-4568-A322-A65D9DD1C279Q63613451-097A82DE-66DC-430A-8A37-721D11C5801EQ63805821-1815558D-EED6-4E15-8322-4E130F36DFA1Q63806679-8AF8BCA2-A8BE-46B1-9200-B65ABF27F675Q63807707-E8961050-A262-47E0-81A3-3335CF64415FQ63807711-BC6380DF-3406-44F4-8F6B-144174E3EFA6Q63807717-DD088D10-6FC6-4B6B-8A7D-7DFD6D64A9B7Q63807719-86957503-EAC4-45F8-B41E-33749E4D2028Q63807720-F3195954-7BB5-49D5-B18D-76F391D779FFQ63807725-8D2861D7-13CC-49A1-9208-D39D7B0AAB95
P1050
Q54798747-AF89947E-D010-4BDE-9792-9614618CF9FBQ54898050-BB9151E3-5419-4235-9244-F9128376661FQ54930407-1904D038-9869-4990-9ECB-A9D01EBE436EQ54930408-8936F80A-8C65-4B03-952C-A228329752B6Q54931146-DD236B17-6226-47B3-8E2A-D5A7F45C8861Q54949779-76D77D1D-8723-42ED-9A72-509076B6CB97Q54949782-D0693219-6854-4717-9AB2-BF4DA31698A6Q54949783-EE4D6BF3-3585-4C30-B5C6-546A72D10415Q54971950-C666A465-A7BD-4DD9-836B-FFFDB49D4D3EQ54971972-2912C2C8-1BCD-4E6D-96F7-F8D6994856C6Q54993094-66BE6517-15F2-4081-A5E7-427FDA63817E
P5166
Q24653517-5012321D-D044-4C41-A5D6-F1E6FDE9A89EQ26829896-426B9599-EDBF-45C1-8222-381B7336A314Q28076555-BC2ACAED-AFA4-419B-898C-E3EF214C9744Q30438459-3B397B5C-6365-4C68-BF39-5C38875E0934Q30869306-09804CDB-5223-4C11-B98F-CBB247AC4562Q33429089-4247B1F0-044D-480A-8E04-DDF8608D7DC8Q34990908-34B466BB-D574-4E0D-9F0A-D0E0134E2145Q37553466-7278C1B8-CE9C-45EF-A8FC-475F4B75CB9EQ37713411-D21BA624-5019-4BCC-BF1F-CB3331DBD280Q41520447-5D57CAA1-FE29-4ACA-AFBF-B8CE63071BA7
P921
description
Tumor des zentralen Nervensystems
@de
anaplastico neoplasia intracraneal del sistema nervioso central
@es
tumor that arises from the ependyma, a tissue of the central nervous system
@en
tumore che origina dall'ependima
@it
опухоль эпендимы — ткани центральной нервной системы
@ru
name
Ependymom
@de
Wyściółczak
@pl
ependimoma
@es
ependimoma
@it
ependimoma
@pt
ependymom
@cs
ependymoma
@en
ependymoom
@nl
épendymome
@fr
епендимом
@sr
type
label
Ependymom
@de
Wyściółczak
@pl
ependimoma
@es
ependimoma
@it
ependimoma
@pt
ependymom
@cs
ependymoma
@en
ependymoom
@nl
épendymome
@fr
епендимом
@sr
altLabel
Ependymoma
@pl
ependimom
@sr
ependimomi
@it
ورم البطانة العصبية
@ar
prefLabel
Ependymom
@de
Wyściółczak
@pl
ependimoma
@es
ependimoma
@it
ependimoma
@pt
ependymom
@cs
ependymoma
@en
ependymoom
@nl
épendymome
@fr
епендимом
@sr
P493
P672
P227
P486
P508
P6366
P646
P1296
P1550
P1748
P1995
P227
P279
P31
P373
Ependymal tumors
P3827
ependymoma